Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Current Medicinal Chemistry

Volumn 22, Issue 3, 2015, Pages 373-404

  Guzior, Natalia ^a   Więckowska, Anna ^a   Panek, Dawid ^a   Malawska, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Antioxidants; Cholinesterase inhibitors; Inhibitors of monoamine oxidase A B; Inhibitors of secretase; Multi target directed ligands; Neuroprotective properties; amyloid anti aggregation properties

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMYLOID BETA PROTEIN; BENZAMIDE DERIVATIVE; BERBERINE DERIVATIVE; BETA SECRETASE; BETA SECRETASE 1; CANNABINOID; CHALCONE DERIVATIVE; CHELERYTHRINE; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; CURCUMIN; DONEPEZIL; EBSELEN; FLAVONOID; GALANTAMINE; HISTAMINE H3 RECEPTOR; MEMANTINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NOOTROPIC AGENT; PYRAZOLINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RHEIN; RIVASTIGMINE; TACRINE; TACRINE DERIVATIVE; THIOCTIC ACID; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; ARTICLE; HUMAN; HYBRID; MEDICINAL CHEMISTRY; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATES;

EID: 84928684146     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141106122628     Document Type: Article

References (232)

1. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med., 2010, 362, 329-344.
2. Huang, Y.; Mucke, L. Alzheimer Mechanisms and Therapeutic Strategies. Cell, 2012, 148, 1204-1222.
3. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol., 2011, 7, 137-152.
4. Reitz, C.; Mayeux, R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol., 2014, 88, 640-651.
5. Bartus, R.; Dean, R.; Beer, B.; Lippa, A. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-414.
6. Terry, A. V. Jr.; Buccafusco, J. J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther., 2003, 306, 821-827.
7. Marksteiner, J.; Schmidt, R. Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions. Drugs Aging, 2004, 21, 415-426.
8. 25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol., 2006, 149, 998-1012.
9. Wilkinson, D. G.; Francis, P. T.; Schwam, E.; Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer's dis ease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging, 2004, 21, 453-478.
10. Rodda, J.; Carter, J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ, 2012, 344, e2986.
11. van Marum, R. J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol., 2008, 22, 265-274.
12. Martinez, A. Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism; RSC: Cambridge, UK, 2010.
13. Martinez, A. Emerging Drugs and Targets for Alzheimer's Disease: Volume 2: Neuronal Plasticity. RSC: Cambridge, UK, 2010.
14. Grill, J. D.; Cummings, J. L. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev. Neurother., 2010, 10, 711-728.
15. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
16. Frisardi, V.; Solfrizzi, V.; Imbimbo, P. B.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.; Panza, F. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res., 2010, 7, 40-55.
17. Rampa, A.; Gobbi, S.; Belluti, F.; Bisi, A. Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment? Curr. Top. Med. Chem., 2013, 13, 1879-1904.
18. Caraci, F.; Bosco, P.; Leggio, G. M.; Malaguarnera, M.; Drago, F.; Bucolo, C.; Salomone, S. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr. Top. Med. Chem., 2013, 13, 1853-1863.
19. Bennett, D. A.; Yu, L.; De Jager, P. L. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem. Pharmacol., 2014, 88, 617-630.
20. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
21. Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.
22. Espinoza-Fonseca, L. M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem., 2006, 14, 896-897.
23. Muller-Schiffmann, A.; Sticht, H.; Korth, C. Hybrid compounds: from simple combinations to nanomachines. BioDrugs, 2012, 26, 21-31.
24. Rapposelli, S.; Balsamo, A. In: Multifunctional drugs: new chimeras in medicinal chemistry; Rapposelli, S., Ed.; Transworld Research Network: Kerala, 2010, pp. 1-17.
25. Nielsch, U.; Schafer, S.; Wild, H.; Busch, A. One target-multiple indications: a call for an integrated common mechanisms strategy. Drug Discov. Today, 2007, 12, 1025-1031.
26. Speck-Planche, A.; Luan, F.; Cordeiro, M. N. Role of ligand-based drug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in Fragment-Based Ligand Design. Curr. Med. Chem., 2012, 19, 1635-1645.
27. Costantino, L.; Barlocco, D. Designed multiple ligands: basic research vs clinical outcomes. Curr. Med. Chem., 2012, 19, 3353-3387.
28. Anand, S.; Vande Vrede, L.; Luo, J.; Thatcher, G. R. J. In: Multifunctional drugs: new chimeras in medicinal chemistry; Rapposelli, S., Ed.; Transworld Research Network: Kerala, 2010, pp. 65-97.
29. Cavalli, A.; Bolognesi, M. L. Multitarget drugs for the treatment of Alzheimer's disease. In Polypharmacology in drug discovery; Peters, J. U., Ed.; Wiley: 2012, 441-448.
30. Iqbal, K.; Grundke-Iqbal, I. Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement., 2010, 6, 420-424.
31. Bolognesi, M. L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer's disease: new approaches to drug discovery. Curr. Opin. Chem. Biol., 2009, 13, 303-308.
32. Calza, L.; Baldassarro, V. A.; Giuliani, A.; Lorenzini, L.; Fernandez, M.; Mangano, C.; Sivilia, S.; Alessandri, M.; Gusciglio, M.; Torricella, R.; Giardino, L. From the multifactorial nature of Alzheimer's disease to multitarget therapy: the contribution of the translational approach. Curr. Top. Med. Chem., 2013, 13, 1843-1852.
33. Decker, M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev. Med. Chem., 2007, 7, 221-229.
34. Musial, A.; Bajda, M.; Malawska, B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem., 2007, 14, 2654-2679.
35. Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem., 2010, 17, 1825-1838.
36. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
37. Minarini, A.; Milelli, A.; Simoni, E.; Rosini, M.; Bolognesi, M. L.; Marchetti, C.; Tumiatti, V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem., 2013, 13, 1771-1786.
38. Viayna, E.; Sabate, R.; Munoz-Torrero, D. Dual inhibitors of betaamyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr. Top. Med. Chem., 2013, 13, 1820-1842.
39. Leon, R.; Garcia, A. G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev., 2013, 33, 139-189.
40. Fernandez-Bachiller, M. I.; Perez, C.; Campillo, N. E.; Paez, J. A.; Gonzalez-Munoz, G. C.; Usan, P.; Garcia-Palomero, E.; Lopez, M. G.; Villarroya, M.; Garcia, A. G.; Martinez, A.; Rodriguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem, 2009, 4, 828-841.
41. Samadi, A.; Valderas, C.; de los Ríos, C.; Bastida, A.; Chioua, M.; González-Lafuente, L.; Colmena, I.; Gandía, L.; Romero, A.; del Barrio, L.; Martín-de-Saavedra, M. D.; López, M. G.; Villarroya, M.; Marco-Contelles, J. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorg. Med. Chem., 2011, 19, 122-133.
42. León, R.; Ríos, C.d.l.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Javier Luque, F.; López, M. G.; García, A. G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Med. Chem., 2008, 16, 7759-7769.
43. Tomassoli, I.; Ismaili, L.; Pudlo, M.; de los Ríos, C.; Soriano, E.; Colmena, I.; Gandía, L.; Rivas, L.; Samadi, A.; Marco-Contelles, J. Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists. Eur. J. Med. Chem., 2011, 46, 1-10.
44. Lange, J. H.; Coolen, H. K.; van der Neut, Martina A. W.; Borst, A. J.; Stork, B.; Verveer, P. C.; Kruse, C. G. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism. J. Med. Chem., 2010, 53, 1338-1346.
45. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-targetdirected coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
46. Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; Wang, X.; Hu, D.; Peng, H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; Zhang, H.; Li, J.; Shen, J. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase. Bioorg. Med. Chem., 2009, 17, 1600-1613.
47. Bertoni, S.; Ballabeni, V.; Flammini, L.; Saccani, F.; Domenichini, G.; Morini, G.; Comini, M.; Rivara, M.; Barocelli, E. In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 378, 335-343.
48. Incerti, M.; Flammini, L.; Saccani, F.; Morini, G.; Comini, M.; Coruzzi, M.; Barocelli, E.; Ballabeni, V.; Bertoni, S. Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H3 Receptor Antagonists Combining Anticholinesterase Activity. ChemMed-Chem, 2010, 5, 1143-1149.
49. Rook, Y.; Schmidtke, K.; Gaube, F.; Schepmann, D.; Wü nsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent β-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem., 2010, 53, 3611-3617.
50. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J. Med. Chem., 2008, 51, 4381-4384.
51. Cappelli, A.; Gallelli, A.; Manini, M.; Anzini, M.; Mennuni, L.; Makovec, F.; Menziani, M. C.; Alcaro, S.; Ortuso, F.; Vomero, S. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties. J. Med. Chem., 2005, 48, 3564-3575.
52. Toda, N.; Kaneko, T.; Kogen, H. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Chem. Pharm. Bull., 2010, 58, 273-287.
53. Fernández-Bachiller, M. I.; Pérez, C.; González-Munoz, G. C.; Conde, S.; López, M. G.; Villarroya, M.; García, A. G.; Rodríguez-Franco, M. I. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem., 2010, 53, 4927-4937.
54. Huang, W.; Lv, D.; Yu, H.; Sheng, R.; Kim, S. C.; Wu, P.; Luo, K.; Li, J.; Hu, Y. Dual-target-directed 1, 3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease. Bioorg. Med. Chem., 2010, 18, 5610-5615.
55. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridkin, M.; Youdim, M. B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease1. J. Neurochem., 2007, 100, 490-502.
56. Zheng, H.; Youdim, M. B.; Fridkin, M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective α neurorestorative moieties for Alzheimer's therapy. J. Med. Chem., 2009, 52, 4095-4098.
57. Hieke, M.; Ness, J.; Steri, R.; Dittrich, M.; Greiner, C.; Werz, O.; Baumann, K.; Schubert-Zsilavecz, M.; Weggen, S.; Zettl, H. Design, synthesis, and biological evaluation of a novel class of β-secretase modulators with PPARβ activity. J. Med. Chem., 2010, 53, 4691-4700.
58. Li, W.; Mak, M.; Jiang, H.; Wang, Q.; Pang, Y.; Chen, K.; Han, Y. Novel anti-Alzheimer's dimer Bis (7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics, 2009, 6, 187-201.
59. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets, 2012, 13, 483-494.
60. Capurro, V.; Busquet, P.; Lopes, J. P.; Bertorelli, R.; Tarozzo, G.; Bolognesi, M. L.; Piomelli, D.; Reggiani, A.; Cavalli, A. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One, 2013, 8, e56870.
61. Carreiras, M. C.; Mendes, E.; Perry, M. J.; Francisco, A. P.; Marco-Contelles, J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem., 2013, 13, 1745-1770.
62. Agis-Torres, A.; Solhuber, M.; Fernandez, M.; Sanchez-Montero, J. M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr. Neuropharmacol., 2014, 12, 2-36.
63. Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multi-targetdirected ligands in Alzheimer's disease treatment. Curr. Med. Chem., 2011, 18, 4949-4975.
64. Lane, R. M.; Potkin, S. G.; Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol., 2006, 9, 101-124.
65. Darvesh, S.; Hopkins, D. A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4, 131-138.
66. Mesulam, M. M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience, 2002, 110, 627-639.
67. Reid, G. A.; Chilukuri, N.; Darvesh, S. Butyrylcholinesterase and the cholinergic system. Neuroscience, 2013, 234, 53-68.
68. Greig, N. H.; Utsuki, T.; Ingram, D. K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q. S.; Mamczarz, J.; Holloway, H. W.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D. K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 17213-17218.
69. Diamant, S.; Podoly, E.; Friedler, A.; Ligumsky, H.; Livnah, O.; Soreq, H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 8628-8633.
70. Podoly, E.; Shalev, D. E.; Shenhar-Tsarfaty, S.; Bennett, E. R.; Ben Assayag, E.; Wilgus, H.; Livnah, O.; Soreq, H. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J. Biol. Chem., 2009, 284, 17170-17179.
71. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65, 407-416.
72. Dinamarca, M. C.; Sagal, J. P.; Quintanilla, R. A.; Godoy, J. A.; Arrazola, M. S.; Inestrosa, N. C. Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease. Mol. Neurodegener., 2010, 5, 4-1326-5-4.
73. Giacobini, E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res., 2004, 50, 433-440.
74. Pepeu, G.; Giovannini, M. G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res., 2009, 6, 86-96.
75. Darreh-Shori, T.; Soininen, H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr. Alzheimer Res., 2010, 7, 67-73.
76. Romero, A.; Cacabelos, R.; Oset-Gasque, M. J.; Samadi, A.; Marco-Contelles, J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett., 2013, 23, 1916-1922.
77. Tang, H.; Zhao, L. Z.; Zhao, H. T.; Huang, S. L.; Zhong, S. M.; Qin, J. K.; Chen, Z. F.; Huang, Z. S.; Liang, H. Hybrids of oxoisoaporphinetacrine congeners: novel acetylcholinesterase and acetylcholinesteraseinduced β-amyloid aggregation inhibitors. Eur. J. Med. Chem., 2011, 46, 4970-4979.
78. Tang, H.; Wei, Y. B.; Zhang, C.; Ning, F. X.; Qiao, W.; Huang, S. L.; Ma, L.; Huang, Z. S.; Gu, L. Q. Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase. Eur. J. Med. Chem., 2009, 44, 2523-2532.
79. Tang, H.; Ning, F. X.; Wei, Y. B.; Huang, S. L.; Huang, Z. S.; Chan, A. S.; Gu, L. Q. Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3765-3768.
80. Ellman, G. L.; Courtney, K. D.; Andres jr., V.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
81. LeVine, H. 3rd Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci., 1993, 2, 404-410.
82. Keri, R. S.; Quintanova, C.; Marques, S. M.; Esteves, A. R.; Cardoso, S. M.; Santos, M. A. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem., 2013, 21, 4559-4569.
83. Leuma Yona, R.; Mazeres, S.; Faller, P.; Gras, E. Thioflavin derivatives as markers for amyloid-beta fibrils: insights into structural features important for high-affinity binding. ChemMedChem, 2008, 3, 63-66.
84. Choi, M. M.; Kim, E. A.; Hahn, H. G.; Nam, K. D.; Yang, S. J.; Choi, S. Y.; Kim, T. U.; Cho, S. W.; Huh, J. W. Protective effect of benzothiazole derivative KHG21834 on amyloid β-induced neurotoxicity in PC12 cells and cortical and mesencephalic neurons. Toxicology, 2007, 239, 156-166.
85. Soto-Ortega, D. D.; Murphy, B. P.; Gonzalez-Velasquez, F. J.; Wilson, K. A.; Xie, F.; Wang, Q.; Moss, M. A. Inhibition of amyloid-β aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. Bioorg. Med. Chem., 2011, 19, 2596-2602.
86. Ozturan Ozer, E.; Tan, O. U.; Ozadali, K.; Kucukkilinc, T.; Balkan, A.; Ucar, G. Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl) acylhydrazone derivatives as dual inhibitors for cholinesterases and Aβ aggregation. Bioorg. Med. Chem. Lett., 2013, 23, 440-443.
87. Ignasik, M.; Bajda, M.; Guzior, N.; Prinz, M.; Holzgrabe, U.; Malawska, B. Design, synthesis and evaluation of novel 2-(aminoalkyl)-isoindoline-1, 3-dione derivatives as dual-binding site acetylcholinesterase inhibitors. Arch. Pharm. (Weinheim), 2012, 345, 509-516.
88. Bajda, M.; Wieckowska, A.; Hebda, M.; Guzior, N.; Sotriffer, C. A.; Malawska, B. Structure-based search for new inhibitors of cholinesterases. Int. J. Mol. Sci., 2013, 14, 5608-5632.
89. Alptuzun, V.; Prinz, M.; Horr, V.; Scheiber, J.; Radacki, K.; Fallarero, A.; Vuorela, P.; Engels, B.; Braunschweig, H.; Erciyas, E.; Holzgrabe, U. Interaction of (benzylidene-hydrazono)-1, 4-dihydropyridines with β-amyloid, acetylcholine, and butyrylcholine esterases. Bioorg. Med. Chem., 2010, 18, 2049-2059.
90. Catto, M.; Berezin, A. A.; Lo Re, D.; Loizou, G.; Demetriades, M.; De Stradis, A.; Campagna, F.; Koutentis, P. A.; Carotti, A. Design, synthesis and biological evaluation of benzo[e][1, 2, 4]triazin-7 (1H) - one and [1, 2, 4]-triazino[5, 6, 1-jk]carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and acetyl/butyryl cholinesterase. Eur. J. Med. Chem., 2012, 58, 84-97.
91. Convertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caflisch, A. 9, 10-Anthraquinone hinders β-aggregation: how does a small molecule interfere with Aβ-peptide amyloid fibrillation? Protein Sci., 2009, 18, 792-800.
92. Karlsson, D.; Fallarero, A.; Brunhofer, G.; Guzik, P.; Prinz, M.; Holzgrabe, U.; Erker, T.; Vuorela, P. Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation. Eur. J. Pharm. Sci., 2012, 45, 169-183.
93. Wu, X.; Qin, G.; Cheung, K. K.; Cheng, K. F. New alkaloids from Isatis indigotica. Tetrahedron, 1997, 53, 13323-13328.
94. Pan, L.; Tan, J. H.; Hou, J. Q.; Huang, S. L.; Gu, L. Q.; Huang, Z. S. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 3790-3793.
95. Yan, J. W.; Li, Y. P.; Ye, W. J.; Chen, S. B.; Hou, J. Q.; Tan, J. H.; Ou, T. M.; Li, D.; Gu, L. Q.; Huang, Z. S. Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation. Bioorg. Med. Chem., 2012, 20, 2527-2534.
96. Huang, L.; Su, T.; Li, X. Natural products as sources of new lead compounds for the treatment of Alzheimer's disease. Curr. Top. Med. Chem., 2013, 13, 1864-1878.
97. Brunhofer, G.; Fallarero, A.; Karlsson, D.; Batista-Gonzalez, A.; Shinde, P.; Gopi Mohan, C.; Vuorela, P. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorg. Med. Chem., 2012, 20, 6669-6679.
98. Anand, P.; Singh, B.; Singh, N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg. Med. Chem., 2012, 20, 1175-1180.
99. Hasan, A.; Khan, K. M.; Sher, M.; Maharvi, G. M.; Nawaz, S. A.; Choudhary, M. I.; Atta-ur-Rahman; Supuran, C. T. Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J. Enzyme Inhib. Med. Chem., 2005, 20, 41-47.
100. Bag, S.; Ghosh, S.; Tulsan, R.; Sood, A.; Zhou, W.; Schifone, C.; Foster, M.; LeVine, H., 3rd; Torok, B.; Torok, M. Design, synthesis and biological activity of multifunctional alpha, beta-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg. Med. Chem. Lett., 2013, 23, 2614-2618.
101. LeVine, H. 3rd Biotin-avidin interaction-based screening assay for Alzheimer's β-peptide oligomer inhibitors. Anal. Biochem., 2006, 356, 265-272.
102. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science, 2000, 290, 150-153.
103. Venugopal, C.; Demos, C. M.; Rao, K. S.; Pappolla, M. A.; Sambamurti, K. Beta-secretase: structure, function, and evolution. CNS Neurol. Disord. Drug Targets, 2008, 7, 278-294.
104. Klaver, D. W.; Wilce, M. C.; Cui, H.; Hung, A. C.; Gasperini, R.; Foa, L.; Small, D. H. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Biol. Chem., 2010, 391, 849-859.
105. Luo, X.; Yan, R. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int. J. Clin. Exp. Pathol., 2010, 3, 618-628.
106. Bjorklund, C.; Oscarson, S.; Benkestock, K.; Borkakoti, N.; Jansson, K.; Lindberg, J.; Vrang, L.; Hallberg, A.; Rosenquist, A.; Samuelsson, B. Design and synthesis of potent and selective BACE-1 inhibitors. J. Med. Chem., 2010, 53, 1458-1464.
107. Ghosh, A. K.; Brindisi, M.; Tang, J. Developing β-secretase inhibitors for treatment of Alzheimer's disease. J. Neurochem., 2012, 120 Suppl. 1, 71-83.
108. Fernandez-Bachiller, M. I.; Perez, C.; Monjas, L.; Rademann, J.; Rodriguez-Franco, M. I. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J. Med. Chem., 2012, 55, 1303-1317.
109. Kennedy, M. E.; Wang, W.; Song, L.; Lee, J.; Zhang, L.; Wong, G.; Wang, L.; Parker, E. Measuring human β-secretase (BACE1) activity using homogeneous time-resolved fluorescence. Anal. Biochem., 2003, 319, 49-55.
110. Mancini, F.; De Simone, A.; Andrisano, V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal. Bioanal. Chem., 2011, 400, 1979-1996.
111. Davalos, A.; Gomez-Cordoves, C.; Bartolome, B. Extending applicability of the oxygen radical absorbance capacity (ORACfluorescein) assay. J. Agric. Food Chem., 2004, 52, 48-54.
112. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem., 2003, 38, 223-232.
113. Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillon, C.; Gonzalez-Munoz, G. C.; Rodriguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Munoz-Torrero, D. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem., 2012, 55, 661-669.
114. Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.; Sabate, R.; Juarez-Jimenez, J.; Perez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N. C.; Munoz-Torrero, D. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. J. Med. Chem., 2014, 57, 2549-2567.
115. Mohamed, T.; Zhao, X.; Habib, L. K.; Yang, J.; Rao, P. P. Design, synthesis and structure-activity relationship (SAR) studies of 2, 4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors. Bioorg. Med. Chem., 2011, 19, 2269-2281.
116. Mohamed, T.; Yeung, J. C.; Rao, P. P. Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 5881-5887.
117. Mohamed, T.; Yeung, J. C.; Vasefi, M. S.; Beazely, M. A.; Rao, P. P. Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2, 4-diamine template. Bioorg. Med. Chem. Lett., 2012, 22, 4707-4712.
118. Peng, D. Y.; Sun, Q.; Zhu, X. L.; Lin, H. Y.; Chen, Q.; Yu, N. X.; Yang, W. C.; Yang, G. F. Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multifunctions on butylcholinesterase, Abeta aggregation, and β-secretase. Bioorg. Med. Chem., 2012, 20, 6739-6750.
119. Jiaranaikulwanitch, J.; Govitrapong, P.; Fokin, V. V.; Vajragupta, O. From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease. Molecules, 2012, 17, 8312-8333.
120. Jiaranaikulwanitch, J.; Boonyarat, C.; Fokin, V. V.; Vajragupta, O. Triazolyl tryptoline derivatives as β-secretase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6572-6576.
121. Sharma, O. P.; Bhat, T. K. DPPH antioxidant assay revisited. Food Chem., 2009, 113, 1202-1205.
122. Weinreb, O.; Mandel, S.; Bar-Am, O.; Amit, T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J. Neural Transm., 2011, 118, 479-492.
123. Song, M. S.; Matveychuk, D.; MacKenzie, E. M.; Duchcherer, M.; Mousseau, D. D.; Baker, G. B. An update on amine oxidase inhibitors: multifaceted drugs. Prog. Neuropsychopharmacol. Biol. Psychiatr., 2013, 44, 118-124.
124. Zheng, H.; Fridkin, M.; Youdim, M. From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel), 2014, 7, 113-135.
125. Bolea, I.; Gella, A.; Unzeta, M. Propargylamine-derived multitargetdirected ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J. Neural. Transm., 2013, 120, 893-902.
126. Bolea, I.; Juárez-Jiménez, J.; de, l. R.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl) methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem., 2011, 54, 8251-8270.
127. Perez, V.; Marco, J. L.; Fernandez-Alvarez, E.; Unzeta, M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol., 1999, 127, 869-876.
128. Bolea, I.; Gella, A.; Monjas, L.; Perez, C.; Rodriguez-Franco, M. I.; Marco-Contelles, J.; Samadi, A.; Unzeta, M. Multipotent, permeable drug ASS234 inhibits Abeta aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. Curr. Alzheimer Res., 2013, 10, 797-808.
129. Bautista-Aguilera, O. M.; Esteban, G.; Bolea, I.; Nikolic, K.; Agbaba, D.; Moraleda, I.; Iriepa, I.; Samadi, A.; Soriano, E.; Unzeta, M.; Marco-Contelles, J. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem., 2014, 75, 82-95.
130. Samadi, A.; de los Rios, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, M.; Andrisano, V.; Galvez, E.; Valderas, C.; Unzeta, M.; Marco-Contelles, J. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem., 2012, 52, 251-262.
131. Lu, C.; Zhou, Q.; Yan, J.; Du, Z.; Huang, L.; Li, X. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2013, 62, 745-753.
132. Sun, Y.; Chen, J.; Chen, X.; Huang, L.; Li, X. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids. Bioorg. Med. Chem. 2013, 21, 7406-7417.
133. Desideri, N.; Bolasco, A.; Fioravanti, R.; Monaco, L. P.; Orallo, F.; Yanez, M.; Ortuso, F.; Alcaro, S. Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J. Med. Chem., 2011, 54, 2155-2164.
134. Karuppasamy, M.; Mahapatra, M.; Yabanoglu, S.; Ucar, G.; Sinha, B. N.; Basu, A.; Mishra, N.; Sharon, A.; Kulandaivelu, U.; Jayaprakash, V. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem., 2010, 18, 1875-1881.
135. Gokhan-Kelekci, N.; Yabanoglu, S.; Kupeli, E.; Salgin, U.; Ozgen, O.; Ucar, G.; Yesilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A. A. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg. Med. Chem., 2007, 15, 5775-5786.
136. Mishra, N.; Sasmal, D. Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 1969-1973.
137. Mishra, N.; Sasmal, D. Additional acetyl cholinesterase inhibitory property of diaryl pyrazoline derivatives. Bioorg. Med. Chem. Lett., 2013, 23, 702-705.
138. Feng, Y.; Wang, X. Antioxidant therapies for Alzheimer's disease. Oxid. Med. Cell Longev., 2012, 2012, 472932.
139. Padurariu, M.; Ciobica, A.; Lefter, R.; Serban, I. L.; Stefanescu, C.; Chirita, R. The oxidative stress hypothesis in Alzheimer's disease. Psychiatr. Danub., 2013, 25, 401-409.
140. Shan, W. J.; Huang, L.; Zhou, Q.; Meng, F. C.; Li, X. S. Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation. Eur. J. Med. Chem., 2011, 46, 5885-5893.
141. Huang, L.; Luo, Z.; He, F.; Lu, J.; Li, X. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg. Med. Chem., 2010, 18, 4475-4484.
142. Huang, L.; Shi, A.; He, F.; Li, X. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2010, 18, 1244-1251.
143. Su, T.; Xie, S.; Wei, H.; Yan, J.; Huang, L.; Li, X. Synthesis and biological evaluation of berberine-thiophenyl hybrids as multifunctional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activity. Bioorg. Med. Chem., 2013, 21, 5830-5840.
144. Maalej, E.; Chabchoub, F.; Samadi, A.; de los Rios, C.; Perona, A.; Morreale, A.; Marco-Contelles, J. Synthesis, biological assessment and molecular modeling of 14-aryl-10, 11, 12, 14-tetrahydro-9Hbenzo[5, 6]chromeno[2, 3-b]quinolin-13-amines. Bioorg. Med. Chem. Lett., 2011, 21, 2384-2388.
145. Maalej, E.; Chabchoub, F.; Oset-Gasque, M. J.; Esquivias-Perez, M.; Gonzalez, M. P.; Monjas, L.; Perez, C.; de los Rios, C.; Rodriguez-Franco, M. I.; Iriepa, I.; Moraleda, I.; Chioua, M.; Romero, A.; Marco-Contelles, J.; Samadi, A. Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9, 10, 11, 12-tetrahydro-7H-benzo[7, 8]chromeno[2, 3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2012, 54, 750-763.
146. Songsiang, U.; Thongthoom, T.; Boonyarat, C.; Yenjai, C. Claurailas A-D, cytotoxic carbazole alkaloids from the roots of Clausena harmandiana. J. Nat. Prod., 2011, 74, 208-212.
147. Thiratmatrakul, S.; Yenjai, C.; Waiwut, P.; Vajragupta, O.; Reubroycharoen, P.; Tohda, M.; Boonyarat, C. Synthesis, biological evaluation and molecular modeling study of novel tacrinecarbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2014, 75, 21-30.
148. Miller, N. J.; Rice-Evans, C. A. Factors influencing the antioxidant activity determined by the ABTS.+ radical cation assay. Free Radic. Res., 1997, 26, 195-199.
149. Sharma, S.; Rakoczy, S.; Brown-Borg, H. Assessment of spatial memory in mice. Life Sci., 2010, 87, 521-536.
150. Luo, W.; Li, Y. P.; He, Y.; Huang, S. L.; Li, D.; Gu, L. Q.; Huang, Z. S. Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents. Eur. J. Med. Chem., 2011, 46, 2609-2616.
151. Sul, D.; Kim, H. S.; Lee, D.; Joo, S. S.; Hwang, K. W.; Park, S. Y. Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci., 2009, 84, 257-262.
152. Chao, X.; He, X.; Yang, Y.; Zhou, X.; Jin, M.; Liu, S.; Cheng, Z.; Liu, P.; Wang, Y.; Yu, J.; Tan, Y.; Huang, Y.; Qin, J.; Rapposelli, S.; Pi, R. Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem. Lett., 2012, 22, 6498-6502.
153. Zhao, R.; Holmgren, A. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J. Biol. Chem., 2002, 277, 39456-39462.
154. Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.; Luo, H. B.; Huang, L.; Li, X. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J. Med. Chem., 2013, 56, 9089-9099.
155. Wilson, S. R.; Zucker, P. A.; Huang, R. R. C.; Spector, A. Development of synthetic compounds with glutathione peroxidase activity. J. Am. Chem. Soc., 1989, 111, 5936-5939.
156. Luo, Z.; Liang, L.; Sheng, J.; Pang, Y.; Li, J.; Huang, L.; Li, X. Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease. Bioorg. Med. Chem., 2014, 22, 1355-1361.
157. Yanovsky, I.; Finkin-Groner, E.; Zaikin, A.; Lerman, L.; Shalom, H.; Zeeli, S.; Weill, T.; Ginsburg, I.; Nudelman, A.; Weinstock, M. Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. J. Med. Chem., 2012, 55, 10700-10715.
158. Chyan, Y. J.; Poeggeler, B.; Omar, R. A.; Chain, D. G.; Frangione, B.; Ghiso, J.; Pappolla, M. A. Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatoninrelated indole structure, indole-3-propionic acid. J. Biol. Chem., 1999, 274, 21937-21942.
159. Ginsburg, I.; Sadovnic, M.; Oron, M.; Kohen, R. Novel chemiluminescenceinducing cocktails, part I: the role in light emission of combinations of luminal with SIN-1, selenite, albumin, glucose oxidase and Co2+. Inflammopharmacology, 2004, 12, 289-303.
160. Rosini, M.; Simoni, E.; Bartolini, M.; Tarozzi, A.; Matera, R.; Milelli, A.; Hrelia, P.; Andrisano, V.; Bolognesi, M. L.; Melchiorre, C. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem., 2011, 46, 5435-5442.
161. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem., 2005, 48, 360-363.
162. Chin, D.; Huebbe, P.; Pallauf, K.; Rimbach, G. Neuroprotective properties of curcumin in Alzheimer's disease - merits and limitations. Curr. Med. Chem., 2013, 20, 3955-3985.
163. Park, S.; Kim, H.; Cho, E.; Kwon, B.; Phark, S.; Hwang, K.; Sul, D. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol., 2008, 46, 2881-2887.
164. Thapa, A.; Vernon, B. C.; De la Peña, K.; Soliz, G.; Moreno, H. A.; López, G. P.; Chi, E. Y. Membrane-mediated neuroprotection by curcumin from amyloid-β-peptide-induced toxicity. Langmuir, 2013, 29, 11713-11723.
165. Fang, L.; Gou, S.; Liu, X.; Cao, F.; Cheng, L. Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives. Bioorg. Med. Chem. Lett., 2014, 24, 40-43.
166. Fang, X.; Fang, L.; Gou, S.; Cheng, L. Design and synthesis of dimethylaminomethyl-substituted curcumin derivatives/analogues: Potent antitumor and antioxidant activity, improved stability and aqueous solubility compared with curcumin. Bioorg. Med. Chem. Lett., 2013, 23, 1297-1301.
167. Bush, A. I.; Tanzi, R. E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics, 2008, 5, 421-432.
168. Zhao, Y.; Zhao, B. Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid. Med. Cell Longev., 2013, 2013, 316523.
169. Rivera-Mancía, S.; Pérez-Neri, I.; Ríos, C.; Tristán-López, L.; Rivera-Espinosa, L.; Montes, S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact., 2010, 186, 184-199.
170. Budimir, A. Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm., 2011, 61, 1-14.
171. Li, X.; Jankovic, J.; Le, W. Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural Transm., 2011, 118, 473-477.
172. Li, R.; Wang, X.; Hu, X.; Kong, L. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease. Bioorg. Med. Chem. Lett., 2013, 23, 2636-2641.
173. Schroeter, H.; Spencer, J.; Rice-Evans, C.; Williams, R. Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun. N-terminal kinase (JNK), c-Jun. and caspase-3. Biochem. J., 2001, 358, 547-557.
174. Kim, H.; Park, B.; Lee, K.; Choi, C. Y.; Jang, S. S.; Kim, Y.; Lee, S. Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid. J. Agric. Food Chem., 2005, 53, 8537-8541.
175. Sugihara, N.; Arakawa, T.; Ohnishi, M.; Furuno, K. Anti- and prooxidative effects of flavonoids on metal-induced lipid hydroperoxidedependent lipid peroxidation in cultured hepatocytes loaded with alpha-linolenic acid. Free Radic. Biol. Med., 1999, 27, 1313-1323.
176. Li, S.; Wang, X.; Xie, S.; Jiang, N.; Wang, K. D.; Yao, H.; Sun, H.; Kong, L. Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2013, 69, 632-646.
177. Xie, S.; Wang, X.; Li, J.; Yang, L.; Kong, L. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. Eur. J. Med. Chem., 2013, 64, 540-553.
178. Li, S.; Jiang, N.; Xie, S.; Wang, K. D.; Wang, X.; Kong, L. Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease. Org. Biomol. Chem., 2014, 12, 801-814.
179. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure, 1999, 7, 297-307.
180. Meng, F.; Mao, F.; Shan, W.; Qin, F.; Huang, L.; Li, X. Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorg. Med. Chem. Lett., 2012, 22, 4462-4466.
181. Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo, Z.; Su, T.; Jiang, H.; Shan, W.; Li, X. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. J. Med. Chem., 2012, 55, 8483-8492.
182. He, Y.; Yao, P.; Chen, S.; Huang, Z.; Huang, S.; Tan, J.; Li, D.; Gu, L.; Huang, Z. Synthesis and evaluation of 7, 8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2013, 63, 299-312.
183. Wang, B.; Mai, Y.; Li, Y.; Hou, J.; Huang, S.; Ou, T.; Tan, J.; An, L.; Li, D.; Gu, L. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2010, 45, 1415-1423.
184. Yang, W.; Wong, Y.; Ng, O. T.; Bai, L.; Kwong, D. W.; Ke, Y.; Jiang, Z.; Li, H.; Yung, K. K.; Wong, M. S. Inhibition of Beta-Amyloid Peptide Aggregation by Multifunctional Carbazole-Based Fluorophores. Angew. Chem. Int. Ed. Engl., 2012, 51, 1804-1810.
185. Richard, T.; Pawlus, A. D.; Iglésias, M.; Pedrot, E.; Waffo-Teguo, P.; Mérillon, J.; Monti, J. Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci., 2011, 1215, 103-108.
186. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
187. Yao, R.; Lu, X.; Guan, Q.; Zheng, L.; Lu, X.; Ruan, B. Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents. Eur. J. Med. Chem,. 2013, 62, 222-231.
188. Sharma, M.; Gupta, Y. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci., 2002, 71, 2489-2498.
189. Jang, J.; Surh, Y. Protective effect of resveratrol on β-amyloidinduced oxidative PC12 cell death. Free Radic. Biol. Med., 2003, 34, 1100-1110.
190. Lu, C.; Guo, Y.; Li, J.; Yao, M.; Liao, Q.; Xie, Z.; Li, X. Design, synthesis, and evaluation of resveratrol derivatives as Aβ1-42 aggregation inhibitors, antioxidants, and neuroprotective agents. Bioorg. Med. Chem. Lett., 2012, 22, 7683-7687.
191. Lu, C.; Guo, Y.; Yan, J.; Luo, Z.; Luo, H.; Yan, M.; Huang, L.; Li, X. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. J. Med. Chem., 2013, 56, 5843-5859.
192. Li, S.; Wang, X.; Kong, L. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur. J. Med. Chem., 2014, 71, 36-45.
193. Cooke, J. P.; Dzau, V. J. Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med., 1997, 48, 489-509.
194. Faraci, F. M. Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation. Am. J. Physiol., 1991, 261, H1038-H1042.
195. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multipotent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett., 2008, 18, 2905-2909.
196. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem., 2008, 51, 713-716.
197. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Lupp, A.; Peng, S.; Fleck, C.; Zhang, Y.; Lehmann, J. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J. Med. Chem., 2008, 51, 7666-7669.
198. Chen, Y.; Sun, J.; Fang, L.; Liu, M.; Peng, S.; Liao, H.; Lehmann, J.; Zhang, Y. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem., 2012, 55, 4309-4321.
199. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, U.; Gasco, A. Water soluble furoxan derivatives as NO prodrugs. J. Med. Chem., 1997, 40, 463-469.
200. Chen, Y.; Sun, J.; Huang, Z.; Liao, H.; Peng, S.; Lehmann, J.; Zhang, Y. NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity. Bioorg. Med. Chem. Lett., 2013, 23, 3162-3165.
201. Chen, Y.; Sun, J.; Huang, Z.; Liao, H.; Peng, S.; Lehmann, J.; Zhang, Y. Design, synthesis and evaluation of tacrine-flurbiprofennitrate trihybrids as novel anti-Alzheimer's disease agents. Bioorg. Med. Chem., 2013, 21, 2462-2470.
202. Chen, Y.; Sun, J.; Peng, S.; Liao, H.; Zhang, Y.; Lehmann, J. Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease. Arch. Pharm. (Weinheim), 2013, 346, 865-871.
203. Fang, L.; Fang, X.; Gou, S.; Lupp, A.; Lenhardt, I.; Sun, Y.; Huang, Z.; Chen, Y.; Zhang, Y.; Fleck, C. Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents. Eur. J. Med. Chem., 2014, 76, 376-386.
204. Greenblatt, H.; Kryger, G.; Lewis, T.; Silman, I.; Sussman, J. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett., 1999, 463, 321-326.
205. Zhang, W.; Ruan, J.; Wu, P.; Jiang, F.; Zhang, L. N.; Fang, W.; Chen, X.; Wang, Y.; Cao, B.; Chen, G. Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly (ADP-ribose) polymerase-1 inhibitors. J. Med. Chem., 2009, 52, 718-725.
206. Wang, Y.; Wang, F.; Yu, J. P.; Jiang, F. C.; Guan, X. L.; Wang, C. M.; Li, L.; Cao, H.; Li, M. X.; Chen, J. G. Novel multipotent phenylthiazole-tacrine hybrids for the inhibition of cholinesterase activity, β-amyloid aggregation and Ca2+ overload. Bioorg. Med. Chem., 2012, 20, 6513-6522.
207. González-Muñoz, G. C.; Arce, M. P.; López, B.; Pérez, C.; Romero, A.; del Barrio, L.; Martín-de-Saavedra, M. D.; Egea, J.; León, R.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S.; Rodríguez-Franco, M. I. N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. Eur. J. Med. Chem., 2011, 46, 2224-2235.
208. Zhang, Z.; Simpkins, J. W. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res., 2010, 1359, 233-246.
209. Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology, 2012, 62, 997-1003.
210. Wood, P. L.; Khan, M. A.; Moskal, J. R. Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine. Brain Res., 2007, 1158, 158-163.
211. Simoni, E.; Daniele, S.; Bottegoni, G.; Pizzirani, D.; Trincavelli, M. L.; Goldoni, L.; Tarozzo, G.; Reggiani, A.; Martini, C.; Piomelli, D. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem., 2012, 55, 9708-9721.
212. Rosini, M.; Simoni, E.; Bartolini, M.; Soriano, E.; Marco-Contelles, J.; Andrisano, V.; Monti, B.; Windisch, M.; Hutter-Paier, B.; McClymont, D. W. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem, 2013, 8, 1276-1281.
213. Bachurin, S.; Bukatina, E.; Lermontova, N.; Tkachenko, S.; Afanasiev, A.; Grigoriev, V.; Grigorieva, I.; Ivanov, Y.; Sablin, S.; Zefirov, N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N. Y. Acad. Sci., 2001, 939, 425-435.
214. Hartbauer, M.; Hutter-Paier, B.; Windisch, M. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. J. Neural Transm., 2001, 108, 581-592.
215. Bisogno, T.; Di Marzo, V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr. Pharm. Des., 2008, 14, 2299-2305.
216. Gowran, A.; Noonan, J.; Campbell, V. A. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci. Ther., 2011, 17, 637-644.
217. Rizzo, S.; Tarozzi, A.; Bartolini, M.; Da Costa, G.; Bisi, A.; Gobbi, S.; Belluti, F.; Ligresti, A.; Allarà, M.; Monti, J. 2-Arylbenzofuranbased molecules as multipotent Alzheimer's disease modifying agents. Eur. J. Med. Chem., 2012, 58, 519-532.
218. González-Naranjo, P.; Pérez-Macias, N.; Campillo, N. E.; Pérez, C.; Arán, V. J.; Girón, R.; Sánchez-Robles, E.; Martín, M. I.; Gómez-Cañas, M.; García-Arencibia, M. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur. J. Med. Chem., 2014, 73, 56-72.
219. Berlin, M.; Boyce, C. W.; de Lera Ruiz, M. Histamine H3 receptor as a drug discovery target. J. Med. Chem., 2011, 54, 26-53.
220. Gemkow, M. J.; Davenport, A. J.; Harich, S.; Ellenbroek, B. A.; Cesura, A.; Hallett, D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today, 2009, 14, 509-515.
221. Singh, M. R.; Jadhav, H. Histamine H3 receptor function and ligands: recent developments. Mini Rev. Med. Chem., 2013, 13, 47-57.
222. Łazewska, D.; Kieć-Kononowicz, K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin. Ther. Pat., 2010, 20, 1147-1169.
223. Petroianu, G.; Arafat, K.; Sasse, B.; Stark, H. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie, 2006, 61, 179-182.
224. Esbenshade, T. A.; Fox, G. B.; Cowart, M. D. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., 2006, 6, 77-88, 59.
225. Bajda, M.; Kuder, K. J.; Łazewska, D.; Kieć-Kononowicz, K.; Wiłckowska, A.; Ignasik, M.; Guzior, N.; Jończyk, J.; Malawska, B. Dual-acting diether derivatives of piperidine and homopiperidine with histamine H3 receptor antagonistic and anticholinesterase activity. Arch. Pharm. (Weinheim), 2012, 345, 591-597.
226. Darras, F. H.; Pockes, S.; Huang, G.; Wehle, S.; Strasser, A.; Wittmann, H.; Nimczick, M.; Sotriffer, C. A.; Decker, M. Synthesis, biological evaluation, and computational studies of tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists. ACS Chem. Neurosci., 2014, 5, 225-242.
227. Darras, F. H.; Kling, B.; Heilmann, J.; Decker, M. Neuroprotective tri- and tetracyclic BChE inhibitors releasing reversible inhibitors upon carbamate transfer. ACS Med. Chem. Lett., 2012, 3, 914-919.
228. Puccio, S.; Chu, J.; Pratico, D. Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PloS One, 2011, 6, e15163.
229. Chu, J.; Praticò, D. Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model: Involvement of γ-Secretase. Am. J. Pathol., 2011, 178, 1762-1769.
230. Firuzi, O.; Zhuo, J.; Chinnici, C. M.; Wisniewski, T.; Pratico, D. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J., 2008, 22, 1169-1178.
231. Chen, Y. P.; Zhang, Z. Y.; Li, Y. P.; Li, D.; Huang, S. L.; Gu, L. Q.; Xu, J.; Huang, Z. S. Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase. Eur. J. Med. Chem., 2013, 66, 22-31.
232. Cummings, J. L.; Morstorf, T.; Zhong, K. Alzheimer's disease drugdevelopment pipeline: few candidates, frequent failures. Alzheimers Res. Ther., 2014, 6, 37.